Experienced in Dementia

Dr. Jeffrey T. Apter

Psychiatry
256 Bunn Dr, Suite 6, 
Princeton, NJ 
Experienced in Dementia
256 Bunn Dr, Suite 6, 
Princeton, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Apter is a Psychiatrist in Princeton, New Jersey. Dr. Apter is rated as an Experienced provider by MediFind in the treatment of Dementia. His top areas of expertise are Alzheimer's Disease, Dementia, and Attention Deficit Hyperactivity Disorder (ADHD).

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 7 clinical trials in the study of Dementia.

Specialties
Psychiatry
Licenses
Psychiatry & Neurology in NJ
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Independent Health
  • EPO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

256 Bunn Dr, Suite 6, Princeton, NJ 08540

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Drug
Study Drug: AGB101
Study Phase: Phase 2/Phase 3
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drug: SPN-812
Study Phase: Phase 3
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: LY3303560
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: July 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
A, Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)
A, Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)
Enrollment Status: Terminated
Publish Date: February 05, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

2 Total Publications

Update on Disease-Modifying/Preventive Therapies in Alzheimer's Disease.
Update on Disease-Modifying/Preventive Therapies in Alzheimer's Disease.
Journal: Current geriatrics reports
Published: November 07, 2015
Similar Doctors
Elite in Dementia
Dr. Daniel Weintraub
Psychiatry
Elite in Dementia
Dr. Daniel Weintraub
Psychiatry

Penn Psychiatry - Penn Center For Rehabilitation And Care

3615 Chestnut Street, Ralston-Penn Center Building, 
Philadelphia, PA 
 (40.6 miles away)
866-301-4724
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Weintraub is a Psychiatrist in Philadelphia, Pennsylvania. Dr. Weintraub is rated as a Distinguished provider by MediFind in the treatment of Dementia. His top areas of expertise are Dementia, Alzheimer's Disease, Major Depression, and Deep Brain Stimulation.

Distinguished in Dementia
Dr. William T. Hu
Psychiatry | Neurology
Distinguished in Dementia
Dr. William T. Hu
Psychiatry | Neurology
125 Paterson St Ste 6100, 
New Brunswick, NJ 
 (13.6 miles away)
732-235-7340
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Hu is a Psychiatrist and a Neurologist in New Brunswick, New Jersey. Dr. Hu is rated as a Distinguished provider by MediFind in the treatment of Dementia. His top areas of expertise are Dementia, Alzheimer's Disease, Primary Lateral Sclerosis, Frontotemporal Dementia, and Hormone Replacement Therapy (HRT). Dr. Hu is currently accepting new patients.

Wei E. Wang
Distinguished in Dementia
Dr. Wei E. Wang
Psychiatry
Distinguished in Dementia
Dr. Wei E. Wang
Psychiatry
35 W Hudson Ave, 
Englewood, NJ 
 (51.7 miles away)
201-408-4487
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients

Wei Wang is a Psychiatrist in Englewood, New Jersey. Dr. Wang is rated as an Elite provider by MediFind in the treatment of Dementia. Her top areas of expertise are Gallbladder Disease, Dementia, Ocular Hypertension (OHT), Endoscopy, and Bone Marrow Aspiration. Dr. Wang is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Apter's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile